# Sagent Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sagent-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Schaumburg, US
- Website: www.sagentpharma.com
- Total disclosed funding: $153M
- Latest round: Series B (Apr 8, 2010)
- Investors on record: 3

## About

Sagent Pharmaceuticals is a specialized firm focused on the development, manufacturing, and marketing of generic injectable pharmaceuticals, addressing critical healthcare needs with innovative solutions.Founded in 2007 and headquartered in Schaumburg, US, Sagent Pharmaceuticals develops and markets generic injectable drugs. The company was involved in a significant transaction in July 2016, when Nichi-Iko Pharmaceuticals agreed to acquire Sagent for USD 736 mn, with the deal expected to close in March 2017. Jeff Yordon and Peter Kaemmerer serve as the CEO of the company. Sagent has completed a total of 6 deals, with the most recent funding round being a Trade Sale in April 2011, raising USD 736 mn.Sagent Pharmaceuticals specializes in the development, manufacturing, and marketing of generic pharmaceuticals, particularly injectable products including vials, prefilled syringes, and premixed bags. These products encompass critical care, oncology, anesthetics, and anti-infective drugs, serving healthcare providers and systems across the United States and select international markets. Their PreventIV Measures® Packaging and Labeling initiative highlights their focus on enhancing patient safety.In the most recent year, 2015, Sagent Pharmaceuticals reported a revenue of USD 318.30 mn and an EBITDA of USD -30.84 mn.Sagent Pharmaceuticals is focused on expanding its product portfolio and entering new markets. The company plans to launch several new injectable products, although specific release dates have not been disclosed. Recent funding from the acquisition by Nichi-Iko Pharmaceuticals will likely be allocated towards these initiatives. The company aims to strengthen its presence in both domestic and international markets, although specific geographic targets have not been specified.

## Funding rounds

- Series B, Apr 8, 2010, $40M — China Renaissance Capital Investment, Zhejiang Hisun Pharmaceutical Co. Ltd.
- Series A, May 20, 2009, $30M — Vivo Capital
- Series A, Sep 4, 2008, $30M — Vivo Capital
- Series A, Sep 26, 2007, $53M — Vivo Capital

## Investors

- Vivo Capital (https://capitalatlas.ai/funds/vivo-capital) — Series A
- China Renaissance Capital Investment (https://capitalatlas.ai/funds/china-renaissance-capital-investment) — Series B
- Zhejiang Hisun Pharmaceutical Co. Ltd. — Series B